BioWorld Asia

Sep. 19, 2007

NeuroSearch Shares Boosted By Tesofensine Obesity Data

Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International) Read More

Ganymed Adds To Series C; Closes 37.2M Financing Round

No Abstract Read More

Gene Expression Levels Vary At Higher Levels Than Thought

Oxford BioMedica Using Sanofi Deal As Catalyst For Growth

European Industry Seeks Wider Links In Orphan Drug Programs

Other News To Note

Renovo Reports Positive Data From Phase IIb Trial Of Juvista

Mutabilis, Oroxcell Collaborate On Preclinical Antibiotic Agent

EU Commissioner Defends Rule Banning GM-Free Zones

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...